Trial Profile
A Phase II Randomized, Double-Blind, Placebo Controlled, Parallel Study of DCB-BO1202 for Alleviating Liver Fibrosis in HBV Patients With Intermediate Hepatocellular Carcinoma Receiving Loco-regional Therapies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs DCB BO1202 (Primary)
- Indications Hepatic fibrosis
- Focus Therapeutic Use
- 10 Jan 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 10 Jan 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.
- 10 Jan 2020 Planned initiation date changed from 1 Feb 2015 to 1 Jan 2020.